# Study to Evaluate D-1553 in Subjects With Solid Tumors

Source: https://onco.cc/trials/nct04585035/  
OnCo record `nct04585035` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Garsorasib, Cetuximab and Pembrolizumab in non-small-cell lung cancer, run by InventisBio Co., Ltd, active and no longer recruiting.

## Summary

Study to Evaluate D-1553 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT04585035 by InventisBio Co., Ltd, with 180 participants enrolled, started 2020-10-02 and due to reach its primary completion in 2024-04-30. Interventions recorded: D-1553 and D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04585035
- Phase: 1/2
- Setting: A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
- Sponsor: InventisBio Co., Ltd
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT04585035: https://clinicaltrials.gov/study/NCT04585035

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Garsorasib](https://onco.cc/drugs/garsorasib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [InventisBio](https://onco.cc/companies/inventisbio/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04585035.json